Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences

On January 5, 2021 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, reported that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021 (Press release, Fortress Biotech, JAN 5, 2021, View Source [SID1234573504]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

10th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.
2021 CTIC 5th Healthcare Investment Digital Summit: The company will present on Saturday, January 9, 2021, at 8:00 p.m. EST.
H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Fortress’ website beginning Monday, January 11, 2021, at 6:00 a.m. EST and will remain available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the presentation.

Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences

On January 5, 2021 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021 (Press release, Mustang Bio, JAN 5, 2021, View Source [SID1234573503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

10th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.
H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Monday, January 11, 2021, at 6:00 a.m. EST.
B. Riley Securities’ Virtual Oncology Investor Conference: The company’s presentation will take place on Thursday, January 21, 2021, at 1:30 p.m. EST and will be available to all conference-registered institutional investors.
Webcasts of the H.C. Wainwright and B. Riley presentations will be available on the Events page of the Investors Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days following each presentation.

OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

On January 5, 2021 OPKO Health, Inc. (NASDAQ: OPK) reported that management will be participating in the 39th Annual J.P. Morgan Healthcare Conference being held virtually on January 11-14, 2021 (Press release, Opko Health, JAN 5, 2021, View Source [SID1234573502]). Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 13th at 3:40 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here.

Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

On January 5, 2021 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST (Press release, Sangamo Therapeutics, JAN 5, 2021, View Source [SID1234573501]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The virtual session will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.

Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

On January 5, 2021 Oncternal Therapeutics (Nasdaq: ONCT), reported that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021 (Press release, Oncternal Therapeutics, JAN 5, 2021, View Source [SID1234573499]). The discussion may cover Oncternal’s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference (Virtual)

Title: Oncternal Therapeutics (ONCT) Fireside Chat
Date: Monday, January 11th 2021
Time: On-demand starting at 6am EST
Presenter: James Breitmeyer, President & CEO

Webcasting Link:

Click Here
Replay Link:
A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at View Source